Journal article · 2021 · Open access
Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes
Advanced Therapeutics, 4(6), 2000262 · Published 24 April 2021 · DOI 10.1002/adtp.202000262
In brief
“Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes” is a 2021 journal article by Rami M. Alzhrani and 7 co-authors, published in Advanced Therapeutics. OpenAlex counts 18 citations as of 21 November 2026, which puts it in the top 8% of works published in 2021 by citations. It is open access: the full text is free to read at PubMed Central.
- Citations
- 18
- Most cited in
- 2025 (4)
- Field-weighted impact
- 1.00
- References
- 213
- Authors
- 8
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with the lowest survival rate among all solid tumors. The lethality of PDAC arises from late detection and propensity of the tumor to metastasize and develop resistance against chemo and radiation therapy. A highly complex tumor microenvironment composed of dense stroma, immune cells, fibroblast, and disorganized blood vessels, is the main obstacle to current PDAC therapy. Despite the tremendous success of immune checkpoint inhibitors (ICIs) in cancers, PDAC remains one of the poorest responders of ICIs therapy. The immunologically "cold" phenotype of PDAC is attributed to the low mutational burden, high infiltration of myeloid-derived suppressor cells and T-regs, contributing to a significant immunotherapy resistance mechanism. Thus, the development of innovative strategies for turning immunologically "cold" tumor into "hot" ones is an unmet need to improve the outcome of PDAC ICIs therapies. Other smart strategies, such as nanomedicines, sonic Hedgehog inhibitor, or smoothened inhibitor, are discussed to enhance chemotherapeutic agents' efficiency by disrupting the PDAC stroma. This review highlights the current challenges and various preclinical and clinical strategies to overcome current PDAC therapy difficulties, thus significantly advancing PDAC research knowledge.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Alzhrani, R. M., Alsaab, H. O., Vanamala, K., Bhise, K., Tatiparti, K., Barari, A., Sau, S., & Iyer, A. K. (2021). Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Advanced Therapeutics, 4(6), 2000262. https://doi.org/10.1002/adtp.202000262
MLA 9
Alzhrani, Rami M., et al. “Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes.” Advanced Therapeutics, vol. 4, no. 6, 2021, p. 2000262. https://doi.org/10.1002/adtp.202000262.
Chicago
Alzhrani, Rami M., Hashem O. Alsaab, Kushal Vanamala, Ketki Bhise, Katyayani Tatiparti, Ayatakshi Barari, Samaresh Sau, and Arun K. Iyer. 2021. “Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes.” Advanced Therapeutics 4 (6): 2000262. https://doi.org/10.1002/adtp.202000262.
Harvard
Alzhrani, R. M. et al. (2021) ‘Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes’, Advanced Therapeutics, 4(6), p. 2000262. doi:10.1002/adtp.202000262.
IEEE
R. M. Alzhrani et al., “Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes,” Advanced Therapeutics, vol. 4, no. 6, p. 2000262, 2021, doi: 10.1002/adtp.202000262.
BibTeX
@article{alzhrani2021overcoming,
title = {{Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes}},
author = {Alzhrani, Rami M. and Alsaab, Hashem O. and Vanamala, Kushal and Bhise, Ketki and Tatiparti, Katyayani and Barari, Ayatakshi and Sau, Samaresh and Iyer, Arun K.},
journal = {Advanced Therapeutics},
year = {2021},
volume = {4},
number = {6},
pages = {2000262},
doi = {10.1002/adtp.202000262},
url = {https://doi.org/10.1002/adtp.202000262}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2021 | 3 | |
| 2022 | 3 | |
| 2023 | 2 | |
| 2024 | 3 | |
| 2025 | 4 | |
| 2026 | 3 |
Its field-weighted citation impact is 1.00: it has been cited 1.00 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- pancreatic ductal adenocarcinoma
- tumor microenvironment
- immune checkpoint inhibitors
- immunotherapy resistance
- cold tumors
- tumor stroma
- myeloid-derived suppressor cells
- regulatory T cells
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Alzhrani, R. M., Alsaab, H. O., Vanamala, K., Bhise, K., Tatiparti, K., Barari, A., Sau, S., & Iyer, A. K. (2021). Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Advanced Therapeutics, 4(6), 2000262. https://doi.org/10.1002/adtp.202000262
How many times has this paper been cited?
18 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the full text from this page.
Who wrote this paper?
Rami M. Alzhrani, Hashem O. Alsaab, Kushal Vanamala, Ketki Bhise, Katyayani Tatiparti, Ayatakshi Barari, Samaresh Sau, Arun K. Iyer.
What is the DOI of this paper?
10.1002/adtp.202000262, permanently at https://doi.org/10.1002/adtp.202000262. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.